Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?

Advanced hepatocellular carcinoma (HCC) remains a formidable health challenge worldwide, with a 5-year survival rate of 2.4% in patients with distant metastases. The hepatocyte growth factor/cellular-mesenchymal-epithelial transition (HGF/c-Met) signaling pathway represents an encouraging therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Shankun, Wu, Weizhou, Jiang, Hao, Ma, Lei, Pan, Chengyi, Jin, Chong, Mo, Jinggang, Wang, Liezhi, Wang, Kunpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600564/
https://www.ncbi.nlm.nih.gov/pubmed/34804015
http://dx.doi.org/10.3389/fimmu.2021.731527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600564/
https://www.ncbi.nlm.nih.gov/pubmed/34804015
http://dx.doi.org/10.3389/fimmu.2021.731527

Ejemplares similares